|
|
I am thrilled to be back at Yale, rejoining the community that has been so instrumental in my education and career, to help propel innovation and entrepreneurship across the university. I look forward to working with some of the most brilliant researchers and students in the world to help accelerate the growth of our dynamic, inclusive entrepreneurial ecosystem in New Haven. As I get started, I am particularly interested in your feedback about how and where we can have the greatest impact. You can reach me at josh.geballe@yale.edu – I look forward to hearing from you.
|
Josh Geballe, MBA
Senior Associate Provost for Entrepreneurship & Innovation at Yale
|
|
|
|
2022 Yale Innovation Summit
May 17-18, 2022
In-person Conference
|
The Yale Innovation Summit is delighted to return to an in-person format this year. The Summit has become the largest entrepreneurship event on campus and the largest gathering of venture capital investors in Connecticut. Over two days we will celebrate innovation and entrepreneurship at Yale, in New Haven and Connecticut as a whole. The Summit offers unequaled networking, education, and inspiration for the entire entrepreneurial ecosystem. All are welcome!
|
|
|
|
IP Insights: Inventorship, Privilege, and Confidentiality: What You and Your Start-Up Need to Know
Virtual Seminar
March 3, 12:00-1:00PM
|
Join Diane K. Harmon & Adam Raymond, J.D., Ph.D. from Pabst Patent Group LLP this Thurs. 3/3 to discuss Inventorship, Privilege, Confidentiality, & Conflict of Interest. Come to listen/watch, or armed with all your questions about the IP process. Participation is highly recommended at Yale's 'IP Insights' sessions!
|
Collab CT organizers are excited to resume networking in March! Although we come from various backgrounds: academia, non-profit, startup, bio, VC, economic development, etc., we understand that the only way to further our individual organizations' missions is to strengthen connections and enhance collaboration. So please join us on March 24 between 4:30 - 6:30pm for a drink, conversation and tasty Bear BBQ appetizers sponsored by Connecticut Innovations!
|
|
|
|
Geballe Named Senior Associate Provost for Entrepreneurship and Innovation |
CALLING YALE INNOVATORS:
Apply Now to Pitch at the 2022 Yale Innovation Summit
|
Two Accelerator Positions Open at OCR:
-
Yale is Seeking Inaugural Program Director to Lead New 'Roberts Fund'
-
'Blavatnik Fund' is seeking new Associate Director
|
|
News We're Following
Includes: Yale and New Haven Ecosystem News, Spinout News, and more.
|
|
Yale Ecosystem News: Yale to make landmark investments in engineering and applied science, FAS
|
|
|
|
Spinout News: Xanadu Bio Obtains Licenses and Options to Novel Platform Technologies from Yale University
|
|
|
|
Ecosystem News: Leading Yale Bioscience Entrepreneurs Sign Leases at New 113,000 SF Elm City Bioscience Center in Downtown New Haven
|
|
|
|
amplifyHERscience News: Melisa Lopez-Anton has been awarded the 2021 Inclusion Grant from WIB-Connecticut
|
|
|
|
Spinout News: QX Therapeutics Has Received FDA Authorization of "Study May Proceed" with a Phase 2 Clinical Trial of QXT-101 for the Prevention and Treatment of PGD in Lung Transplant Recipients
|
|
|
|
Yale Ecosystem News: Yale to Invest in Future Leaders in Medicine, Nursing, and Public Health
|
|
|
|
Yale Entrepreneur-in-Residence News: Bridget Martell has been recognized as one of New Haven Biz's Power 25 - Class of 2022
|
|
|
|
Yale Ecosystem News: Stephen Strittmatter Will Assume Position of Chair of the Department of Neuroscience and Director of the Kavli Institute for Neuroscience
|
|
|
|
Spinout News: Positive Results for Biohaven's Migraine Drug Open Path to Asian Market
|
|
|
|
Spinout News: IsoPlexis' Immune Monitoring Helps Identify Early Factors of Long COVID in Cell Publication
|
|
|
|
Current, state-wide industry news. |
|
Faculty Innovator Spotlight |
|
Dianqing (Dan) Wu
Gladys Phillips Crofoot Professor of Pharmacology
Co-Founder of Qx Therapeutics
|
Overview of current project:
Qx Therapeutics Inc., a Yale University spinout, is a privately held U.S.-based pharmaceutical company founded in 2017. The company focuses on innovative approaches toward unmet medical needs in the pulmonary diseases and organ failure area. Dan and his team just announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s initial Investigational New Drug application (IND) for investigating its lead investigational drug product, QXT-101. QXT-101 is a first in class treatment for patients who suffer from Acute Lung Injury (ALI). It is a fully licensed technology discovered at Yale University under Dr. Dianqing (Dan) Wu’s research laboratory. The mechanism of action (MOA) of QXT-101 involves the MAP3K2/3 pathway. In multiple animal proof of concept studies, this novel MOA is shown to be effective in treatment of ALI and ARDS upon different causes including reperfusion injury. The planned Phase 2 trial will focus on the safety and efficacy of QXT-101 for the prevention and treatment of primary graft dysfunction in lung transplant recipients.
Best advice or key learnings for new innovators: It has been an exciting ride to witness the opening of two INDs based on the intellectual properties invented in my own lab. It would be an ultimate reward for me if the work can be translated into patient care. Looking back, my key learnings are: 1) Work with OCR early and closely throughout the process; OCR's support has been very valuable. 2) Seek support and advice from industry veterans. 3) Establish reliable funding sources. 4) Having a good team led by experienced pharma/biotech individuals and try not to get in their way but providing timely scientific advice and support.
Favorite off-time activities: Sports and travel.
|
|
Share this email on social media! |
|
|
|
FOLLOW OCR
ON SOCIAL MEDIA
|
|
|
|
|
|
|
